AstraZeneca Pharma India (BOM:506820) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Pharma India LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. AstraZeneca Pharma India's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

AstraZeneca Pharma India's long-term debt to total assets ratio declined from Mar. 2023 (0.00) to Mar. 2024 (0.00). It may suggest that AstraZeneca Pharma India is progressively becoming less dependent on debt to grow their business.

AstraZeneca Pharma India LT-Debt-to-Total-Asset Historical Data

The historical data trend for AstraZeneca Pharma India's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Pharma India LT-Debt-to-Total-Asset Chart

AstraZeneca Pharma India Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

AstraZeneca Pharma India Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

AstraZeneca Pharma India LT-Debt-to-Total-Asset Calculation

AstraZeneca Pharma India's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	27.836	/	10780.283
	=	0.00

AstraZeneca Pharma India's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	27.836	/	10780.283
	=	0.00

AstraZeneca Pharma India (BOM:506820) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

AstraZeneca Pharma India LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of AstraZeneca Pharma India's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Pharma India (BOM:506820) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca Pharma India Ltd (BOM:506820) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

ASTRAZEN:India

Address

Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045

Website

https://www.astrazeneca.com

AstraZeneca Pharma India Ltd is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Its only operating segment being Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation and Autoimmunity, Neuroscience and Infection and Vaccines.

AstraZeneca Pharma India (BOM:506820) Headlines

No Headlines